Stay updated on MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial
Sign up to get notified when there's something new on the MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial page.

Latest updates to the MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial page
- Check3 days agoChange DetectedAdded a Locations section with Pennsylvania as a listed site. The HHS Vulnerability Disclosure link and the Pennsylvania Locations entry were removed, and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedPublications section wording updated to clarify that publications are provided by the person entering information about the study, and the revision number is changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedNotice about government funding and operating status has been removed from the page. All substantive study details (title, eligibility criteria, endpoints, and participation information) remain unchanged.SummaryDifference0.4%

- Check54 days agoChange DetectedThe screenshots show only minor formatting and layout adjustments; there are no changes to core study details like eligibility criteria, enrollment, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check83 days agoChange Detected- Added a government-operating-status notice and updated version to v3.2.0; - Removed the resource on Mature T-cell and NK-cell non-Hodgkin lymphoma (GRDIC).SummaryDifference3%

- Check90 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial page.